![]() ![]() “What was impressive was the duration of response for patients, regardless of their PD-L1 status,” Riess said. Median progression-free survival (PFS) was 5.1 months, 4.2 months, and 5.6 months, respectively. In the current update, Riess reported that in patients with PD-L1 expression of 1% or greater, median OS was 17.1 months in the nivolumab plus ipilimumab arm, 15.7 months in the nivolumab alone arm, and 14.9 months in the chemotherapy arm. In part 1b, which focused on patients with PD-L1 expression of 1% or less, patients also were randomly assigned equally to receive the immunotherapy combination (n = 187), nivolumab plus chemotherapy (n = 177), or chemotherapy (n = 186). ![]() In part 1a of the trial, which focused on patients with PD-L1 expression of 1% or greater, 1189 patients were randomly assigned on an equal basis to receive either nivolumab plus ipilimumab (n = 396), nivolumab alone (n = 396), or chemotherapy (n = 397). ![]() The immunotherapy combination also had a significantly higher duration of response (DOR) of 24.5 months for those with positive PD-L1 expression and 19.4 months for those with negative PD-L1 expression vs 6.7 months and 4.8 months with chemotherapy, respectively. The OS was 19% in patients with PD-L1 expression of less than 1%, vs 14% and 7%, respectively, in patients who received chemotherapy. In CheckMate 227, the 5-year rate of OS was 24% in patients who received nivolumab/ ipilimumab and who had PD-L1 expression of at least 1%. Riess, director of thoracic oncology and an associate professor of medicine at UC Davis Health Medical Center in Sacramento, California, noted that recently, 5-year OS data from KEYNOTE-189 (NCT02578680) and KEYNOTE-407 (NCT02775435) had also been presented at the 2022 European Society for Medical Oncology Congress. 1 Findings support the use of nivolumab (Opdivo) and ipilimumab (Yervoy) as a potential firstline approach in advanced non–small cell lung cancer (NSCLC), and were presented at the International Association for the Study of Lung Cancer 2022 North America Conference on Lung Cancer by Jonathan W. The benefits to overall survival (OS) with the use of dual immune checkpoint inhibitors over chemotherapy alone were further confirmed based on results of a 5-year survival update for CheckMate 227 (NCT02477826). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |